Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: Results of a randomized, controlled trial.

Review by :

NATA Review

A nice demonstration again in a placebo controlled trial that recombinant EPO is safe and effective in anemic cancer patients on chemorx. The three times weekly dose is more commonly replaced now with the once weekly dose, starting at 40,000 U SQ.

– David H. Henry

ANEMIA, CANCER, chemotherapy, COMMUNITY ONCOLOGY, DOUBLE-BLIND, epoetin-alpha, erythropoietin, FATIGUE, HEMOGLOBIN LEVELS, INDUCED ANEMIA, MALIGNANT-TUMORS, OF-LIFE, OUTCOMES, QUALITY-OF-LIFE, THERAPY

NATA: Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis

MISSION: Providing a multidisciplinary forum for dialogue between haematologists, transfusion medicine specialists, anaesthesiologists, intensive care and emergency physicians, surgeons, perfusionists, nurses, biomedical scientists and other healthcare professionals.

Sitemap

Contact us

SUBSCRIBE TO OUR NEWSLETTER

Consent Management Platform by Real Cookie Banner

Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: Results of a randomized, controlled trial.

From the Literature

Sitemap

Contact us

Follow us

SUBSCRIBE TO OUR NEWSLETTER